Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

NCT04242173 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Lack of Interest

Conditions

Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: Cemiplimab-Rwlc

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]